Epic Medical Research | Red Oak, TX

Research site
106 Plaza Drive, Red Oak, Texas, United States of America

Site insights

Top conditions

Top treatments


Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 29 total trials

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Chronic Kidney Disease
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Active, not recruiting
Systemic Lupus Erythematosus
Other: Placebo
Drug: Standard-of-care treatment
Locations recently updated

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Drug: Orforglipron
Drug: Placebo

Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.

Drug: Placebo
Drug: EDP-235

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Drug: Placebo
Drug: AD109

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneou...

Systemic Lupus Erythematosus
Drug: Placebo
Drug: Ianalumab

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo for ABBV-552
Drug: ABBV-552

The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adu...

Active, not recruiting
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

Multi-center, open-label, prospective, randomized clinical trial of the aura6000(R) System for the reduction of apnea and hypopneas in adult patients...

Active, not recruiting
Hypopnea, Sleep
Apnea, Obstructive Sleep
Device: Hypoglossal Nerve Stimulation

Trial sponsors

Lilly logo
Pfizer logo
Moderna logo
Novartis logo
AbbVie logo
Exact Sciences Corporation logo
Janssen (J&J Innovative Medicine) logo
Apnimed logo
Enanta Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems